Stealth BioTherapeutics Corp

(NASDAQ:MITO)

Latest On Stealth BioTherapeutics Corp (MITO):

Date/Time Type Description Signal Details
2022-10-01 05:35 ESTNewsStealth Biotherapeutics chief financial officer Robert Weiskopf leaves companyN/A
2022-08-01 21:16 ESTNewsStealth BioTherapeutics stock pops ~20% premarket after co agrees to go privateN/A
2022-07-26 12:19 ESTNewsStealth BioTherapeutics: A Net-Net Biopharma Going PrivateN/A
2022-07-12 05:54 ESTNewsStealth BioTherapeutics receives Nasdaq non-compliance receiptN/A
2022-06-27 22:46 ESTNewsStealth Bio gains after non-binding buyout offerN/A
2022-06-14 11:31 ESTNewsStealth Bio rises on pre-NDA meeting for candidate targeting rare heart conditionN/A
2022-05-31 17:37 ESTNewsStealth Bio's elamipretide gets EMA orphan drug status for muscle disorderN/A
2022-05-12 11:30 ESTNewsStealth Bio climbs on FDA’s Orphan Drug status for lead asset in muscular disorderN/A
2022-05-02 14:59 ESTNewsStealth Bio slips as blindness trial fails to meet main goalN/A
2022-04-11 16:27 ESTNewsStealth BioTherapeutics to raise $8.5M in equity financingN/A
2022-03-24 02:07 ESTNewsStealth stock soars 14% on FDA's orphan drug tag to elamipretide for movement disorderN/A
2022-02-15 17:25 ESTNewsStealth completes patient treatment in phase 2 trial of elamipretide for vision disorderN/A
2022-01-08 10:07 ESTNewsStealth Biotherapeutics receives Nasdaq notification regarding minimum bidN/A
2021-11-11 20:12 ESTNewsStealth BioTherapeutics Corp (MITO) CEO Reenie McCarthy on Q3 2021 Results - Earnings Call TranscriptN/A
2021-10-26 10:22 ESTNewsWarning: MITO is at high risk of performing badlyN/A
2021-10-20 22:55 ESTNewsStealth receives Refuse to File letter for rare disease candidate; shares drop 24%N/A
2021-10-08 02:15 ESTNewsStealth Biotherapeutics soars 8% on preclinical data of potential ALS therapyN/A
2021-09-28 10:37 ESTNewsStealth Bio jumps 9% on positive elamipretide data in pediatric cardiologyN/A
2021-08-24 16:45 ESTNewsStealth Biotherapeutics makes elamipretide NDA submission for Barth syndromeN/A
2021-08-23 22:19 ESTNewsStealth Bio secures two new U.S. patents for elamipretideN/A
2021-08-08 07:13 ESTNewsStealth BioTherapeutics Corp (MITO) CEO Irene McCarthy on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-05 20:47 ESTNewsStealth BioTherapeutics EPS misses by $0.01N/A
2021-08-05 20:46 ESTNewsStealth BioTherapeutics Corp 2021 Q2 - Results - Earnings Call PresentationN/A
2021-07-22 17:47 ESTNewsStealth Biotherapeutics shares soar on EMA orphan drug status for elamipretideN/A
2021-07-22 17:44 ESTNewsStealth Biotherapeutics joins Rare Disease Company CoalitionN/A
2021-05-07 02:28 ESTNewsStealth BioTherapeutics skyrockets on data for elamipretide studyN/A
2021-04-07 09:48 ESTNewsStealth BioTherapeutics shares drop 10% after reporting no 2020 revenues, NDA setbackN/A
2021-04-06 15:33 ESTNewsStealth BioTherapeutics EPS misses by $0.08N/A
2021-04-06 15:33 ESTNewsStealth BioTherapeutics Corp (MITO) CEO Reenie McCarthy on Q4 2020 Results - Earnings Call TranscriptN/A
2021-03-17 17:23 ESTNewsStealth Biotherapeutics promotes Marty Redmon to chief research & development officerN/A
2021-03-17 00:25 ESTAnalyst RatingThe Analyst Target Price has increased from $3.12 to $3.67.Buy
2021-02-19 04:29 ESTNewsCircling Back On Stealth BioTherapeuticsN/A
2021-02-11 01:55 ESTNewsStealth Bio drops 7% on capital raise via direct offeringN/A
2021-01-06 16:21 ESTNewsFDA accepts Stealth Bio's Pre-NDA meeting request for elamipretideN/A
2020-12-23 10:58 ESTAnalyst RatingThe Analyst Target Price has decreased from $3.89 to $3.12.Neutral
2020-12-04 06:39 ESTFinancialsCompany financials have been released.Neutral
2020-11-27 01:07 ESTFinancialsCompany financials have been released.Neutral
2020-11-20 12:49 ESTNewsStealth Bio launches $3.2M registered direct offeringN/A
2020-11-13 00:05 ESTFinancialsCompany financials have been released.Neutral
2020-11-12 00:15 ESTFinancialsCompany financials have been released.Neutral
2020-11-10 15:21 ESTAnalyst RatingThe Analyst Target Price has decreased from $3.95 to $3.89.Neutral
2020-11-08 00:43 ESTNewsStealth BioTherapeutics (MITO) CEO Reenie McCarthy on Q3 2020 Results - Earnings Call TranscriptN/A
2020-11-06 10:49 ESTEarnings EstimateAn EPS average of -$0.02 is estimated for the quarter ending on March 31, 2021.N/A
2020-11-06 00:55 ESTNewsStealth BioTherapeutics EPS in-lineN/A
2020-10-08 21:29 ESTFinancialsCompany financials have been released.Neutral
2020-10-04 15:44 ESTFinancialsCompany financials have been released.Neutral
2020-09-26 16:50 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 18:51 ESTNewsStealth BioTherapeutics (MITO) Investor Presentation - SlideshowN/A
2020-09-17 09:29 ESTFinancialsCompany financials have been released.Neutral
2020-09-08 03:25 ESTAnalyst RatingThe Analyst Target Price has decreased from $4.79 to $3.95.Neutral

About Stealth BioTherapeutics Corp (MITO):

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases. The company's product candidates include SBT-20, a small peptide that targets and binds reversibly to cardiolipin, stabilizing mitochondrial structure, and function under conditions of oxidative stress; and SBT-272, a lead discovery pipeline compound, evaluating for rare neurodegenerative diseases, such as amyotrophic lateral sclerosis. Stealth BioTherapeutics Corp was founded in 2006 and is based in George Town, the Cayman Islands.

MITO Quotes by TradingView

See Advanced Chart

General

  • Name Stealth BioTherapeutics Corp
  • Symbol MITO
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 73
  • Fiscal Year EndDecember
  • IPO Date2019-02-15
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.stealthbt.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 3.7
  • Price/Book (Most Recent Quarter) 44.61
  • Enterprise Value Revenue 4.29
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.02
  • Profit Margin -168%
  • Operating Margin -160%
  • Return on Assets -68%
  • Return on Equity -1186%
  • Revenue 21.09 million
  • Earnings Per Share -$6.67
  • Revenue Per Share $0.5
  • Gross Profit 21.09 million
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 102.55 million
  • EBITDA -75581952
  • Analyst Target Price $3.67
  • Book Value Per Share $0.05
View More

Share Statistics

  • Shares Outstanding 55.43 million
  • Shares Float 12.55 million
  • % Held by Insiders <1%
  • % Held by Institutions 10.43%
  • Shares Short 42178
  • Shares Short Prior Month 81003
  • Short Ratio 0.06
View More

Technicals

  • Beta 2.21
  • 52 Week High $2.5
  • 52 Week Low $1.04
  • 50 Day Moving Average 1.82
  • 200 Day Moving Average 1.53
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Stealth BioTherapeutics Corp (MITO) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Stealth BioTherapeutics Corp (MITO) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-05$N/A-$0.02-$0.020%
2020-06-302020-08-06$N/A-$0.02-$0.0320%
2020-03-312020-05-07$N/A-$0.04-$0.03-23.08%
2019-12-312020-03-31$21.09 million$0.02-$0.02200%
2019-09-302019-11-14$N/A-$0.04-$0.049.09%
2019-06-302019-08-14$N/A-$0.04-$0.0745.43%
2019-03-312019-05-15$N/A-$0.20-$0.17-17.65%

Stealth BioTherapeutics Corp (MITO) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Stealth BioTherapeutics Corp (MITO) Chart:

Stealth BioTherapeutics Corp (MITO) News:

Below you will find a list of latest news for Stealth BioTherapeutics Corp (MITO) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Stealth BioTherapeutics Corp (MITO) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest MITO Trades:

Date Shares Price
Jun 13, 2022 1:33 PM EST200$0.26
Jun 13, 2022 3:33 PM EST100$0.275
Jun 13, 2022 3:51 PM EST100$0.2849
Jun 13, 2022 6:54 PM EST100$0.2825
Jun 13, 2022 7:49 PM EST100$0.2813

Stealth BioTherapeutics Corp (MITO) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-22F-1Registration statement for certain foreign private issuershttps://www.sec.gov/Archives/edgar/data/1696396/000119312520175649/0001193125-20-175649-index.htm
2020-04-08UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1696396/000000000020003013/0000000000-20-003013-index.htm
2020-06-26UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1696396/000000000020005762/0000000000-20-005762-index.htm
2019-07-15SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1696396/000090445419000563/0000904454-19-000563-index.htm
2019-12-31SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1696396/000090445419000761/0000904454-19-000761-index.htm
2020-01-09SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1696396/000090445420000016/0000904454-20-000016-index.htm
2019-03-22SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1696396/000110465919016795/0001104659-19-016795-index.htm
2019-05-24SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1696396/000110465919031740/0001104659-19-031740-index.htm
2020-04-16SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1696396/000110465920047482/0001104659-20-047482-index.htm
2019-02-12CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1696396/000119312519035422/0001193125-19-035422-index.htm
2019-02-14F-1/ARegistration statement for certain foreign private issuershttps://www.sec.gov/Archives/edgar/data/1696396/000119312519039831/0001193125-19-039831-index.htm
2019-02-15POS EXPost-effective amendment adding exhibits to registration statement [Rule 462(d)]https://www.sec.gov/Archives/edgar/data/1696396/000119312519041414/0001193125-19-041414-index.htm
2019-02-15424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1696396/000119312519042577/0001193125-19-042577-index.htm
2019-02-28SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1696396/000119312519057665/0001193125-19-057665-index.htm
2019-03-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1696396/000119312519062828/0001193125-19-062828-index.htm
2019-03-22S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1696396/000119312519083501/0001193125-19-083501-index.htm
2019-04-0420-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1696396/000119312519097880/0001193125-19-097880-index.htm
2019-05-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1696396/000119312519148015/0001193125-19-148015-index.htm
2019-08-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1696396/000119312519221244/0001193125-19-221244-index.htm
2019-09-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1696396/000119312519236687/0001193125-19-236687-index.htm
2019-10-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1696396/000119312519265555/0001193125-19-265555-index.htm
2019-11-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1696396/000119312519291728/0001193125-19-291728-index.htm
2019-12-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1696396/000119312519321131/0001193125-19-321131-index.htm
2020-01-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1696396/000119312520003128/0001193125-20-003128-index.htm
2020-03-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1696396/000119312520073902/0001193125-20-073902-index.htm
2020-04-02S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1696396/000119312520094871/0001193125-20-094871-index.htm
2020-04-02F-3Registration statement by foreign private issuershttps://www.sec.gov/Archives/edgar/data/1696396/000119312520094875/0001193125-20-094875-index.htm
2020-04-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1696396/000119312520098086/0001193125-20-098086-index.htm
2020-04-08CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1696396/000119312520101261/0001193125-20-101261-index.htm
2020-04-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1696396/000119312520104863/0001193125-20-104863-index.htm
2020-05-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1696396/000119312520135672/0001193125-20-135672-index.htm
2020-06-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1696396/000119312520159502/0001193125-20-159502-index.htm
2020-06-22F-1Registration statement for certain foreign private issuershttps://www.sec.gov/Archives/edgar/data/1696396/000119312520175649/0001193125-20-175649-index.htm
2020-07-08CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1696396/000119312520189629/0001193125-20-189629-index.htm
2020-07-10424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1696396/000119312520191140/0001193125-20-191140-index.htm
2020-08-07424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1696396/000119312520212240/0001193125-20-212240-index.htm
2020-08-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1696396/000119312520212242/0001193125-20-212242-index.htm
2020-08-07424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1696396/000119312520212247/0001193125-20-212247-index.htm
2019-02-14F-6/ARegistration of American Depository Receipt shares, not immediately effectivehttps://www.sec.gov/Archives/edgar/data/1696396/000119380519000212/0001193805-19-000212-index.htm
2019-02-14CERTCertificationhttps://www.sec.gov/Archives/edgar/data/1696396/000135445719000071/0001354457-19-000071-index.htm
2020-04-0120-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1696396/000156459020014804/0001564590-20-014804-index.htm
2020-08-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1696396/000156459020037269/0001564590-20-037269-index.htm
2020-11-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1696396/000156459020050587/0001564590-20-050587-index.htm
2020-11-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1696396/000156459020050895/0001564590-20-050895-index.htm
2019-10-15DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1696396/000169639619000002/0001696396-19-000002-index.htm
2020-04-13DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1696396/000169639620000001/0001696396-20-000001-index.htm
2019-02-14EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1696396/999999999519000269/9999999995-19-000269-index.htm
2019-02-14EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1696396/999999999519000278/9999999995-19-000278-index.htm
2020-04-10EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1696396/999999999520000726/9999999995-20-000726-index.htm
2020-07-10EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1696396/999999999520001763/9999999995-20-001763-index.htm
2019-02-15CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1696396/999999999719000374/9999999997-19-000374-index.htm